Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 665-672

  Gómez Gómez, Yazmín ^a   Organista Nava, Jorge ^a   Saavedra Herrera, Mónica Virginia ^a   Rivera Ramírez, Ana Bertha ^b   Terán Porcayo, Marco Antonio ^b   del Carmen Alarcón Romero, Luz ^a   Illades Aguiar, Berenice ^a   Leyva Vázquez, Marco Antonio ^a  

^a Guerrero State University   (Mexico)

^b Arturo Beltrán Ortega Cancer Institute   (Mexico)

Author keywords

A317G polymorphism; Acute lymphoblastic leukemia; C829T polymorphism; Dihydrofolate reductase; Risk of relapse; Survival in acute lymphoblastic leukemia

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIHYDROFOLATE REDUCTASE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEXICO; MORTALITY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD;

EID: 84857011814     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.447     Document Type: Article

References (32)

1. Coronel-Morán QR: Importancia del laboratorio en el diagnóstico y pronóstico de leucemia aguda linfoblástica de la infancia. Acta Pediátrica de México 26: 129-136, 2005.
2. Mejia-Arangure JM, Bonilla M, Lorenzana R, et al: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer 5: 33, 2005.
3. Salud/INEGI, S.d., Fuente: base de datos de defunciones INEGI/Secretaria de Salud, Dirección General de Información en Salud, México. Información disponible en URL www.inegi.org.mx/ (Accessed April, 2008).
4. Cheok MH and Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6: 117-129, 2006.
5. Hider SL, Bruce IN and Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford) 46: 1520-1524, 2007.
6. Wang L, Goodey NM, Benkovic SJ and Kohen A: Coordinated effects of distal mutations on environmentally coupled tunneling in dihydrofolate reductase. Proc Natl Acad Sci USA 103: 15753-15758, 2006.
7. Volpato JP, Fossati E and Pelletier JN: Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase. J Mol Biol 373: 599-611, 2007.
8. Allemann RK, Evans RM, Tey LH, et al: Protein motions during catalysis by dihydrofolate reductases. Philos Trans R Soc Lond B Biol Sci 361: 1317-1321, 2006.
9. Fotoohi AK: Resistance of human leukaemia cells to the antimetabolites. Oncology-Pathology, Suecia 1: 1-84, 2007.
10. Serra M, Reverter-Branchat G, Maurici D, et al: Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 5: 151-160, 2004.
11. De Jonge R, Hooijberg JH, van Zelst BD, et al: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106: 717-720, 2005.
12. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181, 2007.
13. Goto Y, Yue L, Yokoi A, et al: A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 7: 1952-1956, 2001.
14. Dulucq S, St-Onge G, Gagne V, et al: DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 111: 3692-3700, 2008.
15. Seguro-popular: Secretaria de Salud/ Seguro Popular, Información disponible en URL http://www.seguro-popular.salud.gob.mx/ (Accessed May, 2009).
16. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84: 3122-3133, 1994.
17. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14: 18-24, 1996.
18. Merante F, Raha S, Reed JK and Proteau G: The simultaneous isolation of RNA and DNA from tissues and cultured cells. Methods Mol Biol 58: 3-9, 1996.
19. Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, et al: Polymorphisms of the γ-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leukemia Res 34: 728-732, 2010.
20. Kooloos WM, Wessels JAM, van der Straaten T, Allaart CF, Huizinga TWJ and Guchelaar HJ: Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11: 163-175, 2010.
21. Gellekink H, Blom HJ, van der Linden IJ and den Heijer M: Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels. Eur J Hum Genet 15: 103-109, 2007.
22. Mishra PJ, Longo GSA, Menon LG, Abali EE, Humeniuk R, Cole PD, Kamen BA, Banerjee D and Bertino JR: The 829C-T single nucleotide polymorphism in the 30 UTR of the dihydrofolate reductase gene results in methotrexate resistance and is rare among non-Japanese American patients. Proc Amer Assoc Cancer Res 301: 1274, 2006.
23. Parle-McDermott A, Pangilinan F, Mills JL, et al: The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet Part A 143: 1174-1180, 2007.
24. Ng SM, Lin HP, Ariffin WA, Zainab AK, Lam SK and Chan LL: Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol. J Trop Pediatr 46: 338-343, 2000.
25. Frankel LS, Ochs J, Shuster JJ, et al: Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 19: 35, 1997.
26. Shuster JJ, Wacker P, Pullen J, et al: Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 16: 2854-2863, 1998.
27. Kim K, Kang SB, Chung HH, Kim JW, Park NH and Song YS: XRCC1 Arginine 194 Tryptophan and GGH-401 Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 111: 509-515, 2008.
28. Dervieux T, Greenstein N and Kremer J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54: 3095-3103, 2006.
29. Chessells JM, Veys P, Kempski H, et al: Long term follow up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123: 396-405, 2003.
30. Chen SH, Yang CP, Hung IJ, Jaing TH, Shih LY and Tsai MH: Clinical features, molecular diagnosis, and treatment outcome of infants with leukemia in Taiwan. Pediatr Blood Cancer 55: 1264-1271, 2010.
31. Daniel-Cravioto A, Gonzalez-Bonilla CR, Mejia-Arangure JM, et al: Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City. Leuk Lymphoma 50: 1352-1360, 2009.
32. Bernaldez-Rios R, Ortega-Alvarez MC, Perez-Saldivar ML, Alatoma-Medina NE and del Campo-Martinez M: The age incidence of childhood B-cell precursor acute lymphoblastic leukemia in Mexico City. J Pediatr Hematol/Oncol 30: 199-203, 2008.